[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100339170":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Wayne State University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using opioids (40 patients per group).",[13],"Other: Multi-domain assessment battery",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using benzodiazepines (BZD) (40 patients per group).",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3","Patients either newly admitted to Substance Use Disorder treatment in Wayne County, or in treatment longer but are using BZD\u002Fopioid (40 patients per group).",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Multi-domain assessment battery","Assessments of emotion regulation, neurocognitive performance, pain, sleep, and substance use. There is no therapeutic intervention; all participants are already independently in treatment for their substance use disorder and we are simply assessing them at baseline visit and 3-month follow-up.",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Mark Greenwald, PhD","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Heidi Aguas","CONTACT","3139933960","gh7962@wayne.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Tolan Park Medical Building","RECRUITING","Detroit","Michigan","48201","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-83.04575,42.33143,{"lat":50,"lon":49},[53],{"name":33,"role":34,"phone":54,"phoneExt":10,"email":36},"313-993-3960",{"type":30,"investigatorFullName":29,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor","100339170","opioidbenzodiazepine-polydrug-abuse-100339170",false,"NCT03696017","Opioid\u002FBenzodiazepine Polydrug Abuse","Opioid\u002FBenzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies","Inclusion Criteria:\n\n* Recently admitted and\u002For not clinically stable in treatment for Substance Use Disorder (SUD) in Wayne County\n* Using opioids, benzodiazepines (BZD), or BZD\u002Fopioid.\n\nExclusion Criteria:\n\n* Participants with current psychosis, bipolar disorder, or severe depression (i.e. severe psychiatric disorder)\n* Individuals with serious neurological disorders, e.g. brain tumor, history of stroke, history of traumatic brain injury w\u002F loss of consciousness\n* Cognitive impairment (IQ\\\u003C80)","ALL","18 Years","70 Years",{"count":68,"type":69},120,"ESTIMATED","OBSERVATIONAL","Benzodiazepine (BZD)\u002Fopioid polysubstance abuse (PSA) dramatically increases risks of overdose, disability and death; however, little is known about phenotypes that could be targeted to decrease this use and these associated risks.\n\nThe opioid abuse epidemic is generating unprecedented numbers of overdoses (OD) and deaths from prescribed and illegal sources (e.g. fentanyl combined with, or sold as, heroin). Yet, medical and epidemiological data suggest these adverse outcomes are not solely due to over-consumption of opioids.The FDA recognizes the health danger of BZD\u002Fopioid PSA, and issued labeling changes for prescribing BZDs and opioids. Impact of these changes is unclear and could be minimal if people obtain these substances illegally.\n\nBZD abuse can be harmful alone or combined with opioids, as BZDs: (a) contribute to OD\u002Fdeath e.g. 31% of opioid OD-related deaths from 1999 to 2011 were related to coincident BZD use, BZD co-use is dose-dependently related to mortality and rates of BZD OD deaths have sharply increased. (b) exacerbate progression and adverse outcomes of opioid abuse. and (c) worsen behavioral impairment from opioids, increase rates of falls and fractures, motor vehicle accidents, and sleep-disordered breathing.\n\nThere has been limited systematic research of BZD\u002Fopioid PSA. This is a major gap because BZD are often co-prescribed with opioids (in 33 to 50% of cases) and are easily obtained illegally.\n\nIn response to these problems, there is an urgent need to obtain population-level, clinical pharmacology, and mechanistic data to test our unified hypothesis of dual-deficit in affective\u002Fhedonic regulation.",[73],"Polysubstance Abuse",[75,76],"Opioid Abuse","Benzodiazepine abuse","2025-12-26",{"date":79,"type":80},"2025-12-30","ACTUAL",{"date":82,"type":80},"2019-02-08",{"date":84,"type":69},"2026-12",{"name":5,"class":6},1]